Syndax Pharmaceuticals Inc SNDX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Syndax Pharmaceuticals Inc reported revenue across 1 business segments; the largest, Biopharmaceutical Cancer Therapeutics, was $172M, 100.0% of the filed sum (+627.8% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Biopharmaceutical Cancer Therapeutics$172M100.0%+627.8% yoy
Members sum to the consolidated $172M for this period.
- Net Product Revenues$125M72.4%+1525.6% yoy
- Collaboration Revenue$42.4M24.6%no prior
- Milestone Revenue$5.14M3.0%-67.9% yoy
Members sum to the consolidated $172M for this period.
- Biopharmaceutical Cancer Therapeutics$64.9M100.0%+223.6% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.